Business Wire4d
Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program
We anticipate further reducing our annual burn to an annualized rate of approximately $50 million by mid-2025 through the externalization of development costs associated with BOT/BAL, monetization ...
Indiatimes3d
Bal Pharma Share Price
Bal Pharma Ltd., incorporated in the year 1987, is a Small Cap company (having a market cap of Rs 129.99 Crore) operating in Pharmaceuticals sector. Bal Pharma Ltd. key Products/Revenue Segments ...